Skip to main content
LXRX
NASDAQ Life Sciences

Lexicon Pharmaceuticals Reports Near-Breakeven Q1, Driven by $20M Milestone & Key Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.66
Mkt Cap
$677.889M
52W Low
$0.514
52W High
$1.95
52W Position info
223% above low
Off High info
15% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LXRX has more than doubled off its 52-week low of $0.514.

Summary

Lexicon Pharmaceuticals reported significantly improved first-quarter 2026 financial results, achieving a near-breakeven net loss of $1.0 million, primarily due to a $20 million milestone payment from Novo Nordisk, alongside positive updates on its clinical pipeline.


Key Events · Corporate Governance and Compliance · LXRX

  • Achieves Near-Breakeven Net Loss

    Reported a net loss of only $1.0 million for Q1 2026, a significant improvement from a $25.3 million loss in Q1 2025, driven by increased revenues and reduced operating expenses.

  • Secures $20 Million Novo Nordisk Milestone

    Received a $20.0 million development milestone payment from Novo Nordisk related to the initiation of a Phase 1 study for LX9851, reinforcing its financial position.

  • Advances ZYNQUISTA Towards Resubmission

    Remains on track for a mid-2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, with potential for regulatory approval this year.

  • Pilavapadin Cleared for Phase 3

    The FDA raised no objections to advancing pilavapadin (LX9211) into Phase 3 development for diabetic peripheral neuropathic pain.


Analysis · LXRX · Life Sciences

This filing signals a strong operational and financial turnaround for Lexicon Pharmaceuticals. The dramatic reduction in net loss, from $25.3 million to just $1.0 million, is a critical positive development, largely fueled by the $20 million development milestone from Novo Nordisk for LX9851. This non-dilutive capital infusion, combined with a strengthened cash position of nearly $200 million, significantly extends the company's financial runway. Furthermore, the anticipated mid-2026 NDA resubmission for ZYNQUISTA in type 1 diabetes and the FDA's clearance for Phase 3 development of Pilavapadin represent substantial near-term catalysts. Investors should view these updates as strong indicators of pipeline advancement and improved financial health, potentially de-risking the investment thesis.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LXRX was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $677.9M. The 52-week trading range was $0.51 to $1.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LXRX - Latest Insights

LXRX
Nov 05, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.50 info
Change: -$0.1106 (-7%) info
Market Cap: $681.209M info
LXRX
Nov 05, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.50 info
Change: -$0.1075 (-7%) info
Market Cap: $681.209M info
LXRX
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.50 info
Change: -$0.1075 (-7%) info
Market Cap: $681.209M info
LXRX
Aug 31, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.50 info
Change: -$0.7975 (-35%) info
Market Cap: $681.209M info
LXRX
Aug 24, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $1.50 info
Change: -$0.8775 (-37%) info
Market Cap: $681.209M info